Med hub: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) No edit summary |
Usama Talib (talk | contribs) No edit summary |
||
Line 74: | Line 74: | ||
==Experimentation== | ==Experimentation== | ||
{{Drop down list|Name=Resources|Value1=[[Cardiology]]|Value2=[[Endocrinology]]|Value3=[[Pulmonology]]|Value4=[[Rheumatology]]|Value5=[[Nephrology]]|Value6=[[Infectious disease|ID]]|Value7=[[Hematology|Heme/Onc]]|Value8=[[Gastroenterology|GI]]|}} | {{Drop down list|Name=Resources|Value1=[[Cardiology]]|Value2=[[Endocrinology]]|Value3=[[Pulmonology]]|Value4=[[Rheumatology]]|Value5=[[Nephrology]]|Value6=[[Infectious disease|ID]]|Value7=[[Hematology|Heme/Onc]]|Value8=[[Gastroenterology|GI]]|}} | ||
===1=== | ===1=== | ||
{| | |||
|style= "width: 180px; padding-left:15px; padding-right:15px; border:0px; text-align:center;" rowspan="5"|[[Image:Gibson_Michael_circle.png|150px|link=]] | |||
|- | |||
|style= "text-align:center; font-size:22px;" colspan="4"|'''Dr. C. Michael Gibson Presents: AEGIS-1 – The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial''' | |||
|- | |||
| | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/8/86/AEGIS-I_Gibson.pptx '''AEGIS-I Slides'''] | |||
| | |||
|- | |||
|style= "text-align:center; font-size:22px;"|[http://tv.clinicaltrialresults.org/play.php?submission_id=1929 '''Narrated Slide Set'''] | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/a/a3/CIRCULATIONAHA.116.025687.full.pdf '''Circulation Manuscript'''] | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/6/63/AEGIS-I_Investigator_Slide_Deck.pptx '''Investigator Slide Deck'''] | |||
|- | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/f/f0/FINAL_AEGIS-I_Press_Release_8Nov.2016.pdf '''Press Release'''] | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/2/27/FINAL_AEGIS-I_Investigator_QA_09Nov2016_.pdf '''Investigator Q&A'''] | |||
|style= "text-align:center; font-size:22px;"|[https://aegis2.bidmc.org/images/9/90/FINAL_AHA_Late-Breaking_Lipid_Trials_QA_10Nov2016.pdf '''Lipid Trials Q&A'''] | |||
|} | |||
===2=== | |||
<!DOCTYPE html> | <!DOCTYPE html> | ||
<html> | <html> |
Revision as of 16:09, 11 May 2018
Beth Israel Deaconess Medical Center
Template:Collapse top Sample contents text Template:Collapse bottom
Overview
- BIDMC is the official hospital of the Red Sox. It is located in Boston, MA.
Resources
Curriculum |
Events
Events |
Experimentation
1
File:Gibson Michael circle.png | |||
Dr. C. Michael Gibson Presents: AEGIS-1 – The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Human ApoA-I, After Acute Myocardial Infarction - The ApoA-I Event Reduction in Ischemic Syndromes I (AEGIS-I) Trial | |||
AEGIS-I Slides | |||
Narrated Slide Set | Circulation Manuscript | Investigator Slide Deck | |
Press Release | Investigator Q&A | Lipid Trials Q&A |
2
<!DOCTYPE html> <html> <head> <meta name="viewport" content="width=device-width, initial-scale=1"> <style> .dropbtn {
background-color: #4CAF50; color: white; padding: 16px; font-size: 16px; border: none;
}
.dropdown {
position: relative; display: inline-block;
}
.dropdown-content {
display: none; position: absolute; background-color: #f1f1f1; min-width: 160px; box-shadow: 0px 8px 16px 0px rgba(0,0,0,0.2); z-index: 1;
}
.dropdown-content a {
color: black; padding: 12px 16px; text-decoration: none; display: block;
}
.dropdown-content a:hover {background-color: #ddd}
.dropdown:hover .dropdown-content {
display: block;
}
.dropdown:hover .dropbtn {
background-color: #3e8e41;
} </style> </head> <body>
Hoverable Dropdown
Move the mouse over the button to open the dropdown menu.
<button class="dropbtn">Dropdown</button>
<a href="#">Link 1</a> <a href="#">Link 2</a> <a href="#">Link 3</a>
</body> </html>
Nate Test